HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Abstract
Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy. Here, we tested a clinically applicable RNA-based assay that combines ERBB2 and the HER2-enriched (HER2-E) intrinsic subtype in HER2-positive disease treated with dual HER2-blockade without chemotherapy.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 30, 2019
- Source ID
- 10.1093/jnci/djz042
Entities
People
- Aleix Prat
- Andres Forero
- Anne C Pavlick
- Antonio C. Wolff
- Antonio Llombart-cussac
- Barbara Adamo
- Begoña Bermejo
- Brent Rexer
- C. Kent Osborne
- Carmine De Angelis
- Carolina Gutierrez
- Fara Brasó-maristany
- Gaia Griguolo
- Ian Krop
- Jamunarani Veeraraghavan
- Javier Cortés
- Joel S Parker
- Jorge S Reis-Filho
- Laia Paré
- Mafalda Oliveira
- Maria Vidal
- Maria Vittoria Dieci
- Miguel Izquierdo
- Mothaffar F Rimawi
- Paolo Nuciforo
- Patricia Galván
- Pierfranco Conte
- Rachel Schiff
- Roberta Fasani
- Serafín Morales
- Susan Hilsenbeck
- Tao Wang
- Tomás Pascual
- Valentina Guarneri
- Vanessa Rodrik-outmezguine
Organizations
- Banco Bilbao Vizcaya Argentaria
- Baylor College of Medicine
- Carlos III Health Institute
- Dana–Farber Cancer Institute
- GSK
- Hospital Clinic of Barcelona
- Istituto Oncologico Veneto
- Johns Hopkins University
- Memorial Sloan Kettering Cancer Center
- National Institutes of Health
- Novartis
- Spanish Association Against Cancer
- The Breast Cancer Research Foundation
- United States Department of Defense
- University of Alabama at Birmingham
- University of North Carolina
- University of Padua
- Vall d'Hebron Hospital Universitari
- Vanderbilt University